Author

J. Ricketts

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

N. Beutler· 6 shared M. Parren· 5 shared D. Huang· 4 shared D. M. Smith· 4 shared D. Nemazee· 4 shared D. R. Burton· 4 shared G. Song· 4 shared L. Peng· 4 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

N. Beutler

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques

W.-t. He, M. Yuan, S. Callaghan, R. Musharrafieh, G. Song, M. Silva, N. Beutler, W.-H. Lee, P. Yong, J. L. Torres, M. Melo, P. Zhou, F. Zhao, X. Zhu, L. Peng, , R. Andrabi

This study shows that rhesus macaques can be immunized to produce broadly neutralizing antibodies against multiple SARS-related viruses, highlighting differences in B cell repertoires between humans and macaques.

bioRxiv · Jul 5, 2021Immunology

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19

M. A. Bakowski, N. Beutler, E. Chen, T.-T. H. Nguyen, M. G. Kirkpatrick, M. Parren, L. Yang, J. Ricketts, A. K. Gupta, M. V. Hull, P. G. Schultz, D. R. Burton, A. K. Chatterjee, C. W. McNamara, T. F. Rogers

The paper identifies 66 compounds that inhibit SARS-CoV-2 replication and 24 that synergize with remdesivir, suggesting potential oral drug repositioning candidates for COVID-19.

Nature Communications · Jun 3, 2021Peer-reviewedMicrobiology

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

P. Zhou, M. Yuan, G. Song, N. Beutler, N. Shaabani, D. Huang, W.-t. He, X. Zhu, S. Callaghan, P. Yong, F. Anzanello, L. Peng, J. Ricketts, M. Parren, E. Garcia, , R. Andrabi

This study identifies a broadly neutralizing antibody that targets a conserved site on beta-coronavirus spike proteins and provides protection against SARS-CoV-2 infection.

bioRxiv · Mar 30, 2021Immunology

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

G. Song, W.-t. He, S. Callaghan, F. Anzanello, D. Huang, J. Ricketts, J. L. Torres, N. Beutler, L. Peng, S. Vargas, J. Cassell, M. Parren, L. Yang, C. Ignacio, D. M. Smith, , R. Andrabi

The paper examines cross-reactive serum and memory B cell responses to SARS-CoV-2 and endemic coronaviruses, finding weak serum cross-reactivity but stronger memory B cell cross-reactivity.

bioRxiv · Sep 22, 2020Immunology

Machine Learning Models Identify Inhibitors of SARS-CoV-2

V. O. Gawriljuk, P. P. Kyaw Zin, D. H. Foil, J. Bernatchez, S. Beck, N. Beutler, J. Ricketts, L. Yang, T. Rogers, A. C. Puhl, K. M. Zorn, T. R. Lane, A. S. Godoy, G. Olivia, J. L. Siqueira-Neto, , S. Ekins

The paper uses machine learning to predict SARS-CoV-2 inhibitors from FDA-approved compounds, identifying CPI1062 and CPI1155 as potential antiviral drugs.

bioRxiv · Jun 16, 2020Pharmacology & Toxicology

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model

T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W.-t. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, , D. Burton

This study rapidly identifies potent SARS-CoV-2 neutralizing antibodies and demonstrates their protective efficacy in an animal model.

bioRxiv · May 11, 2020Immunology